DexTech Medical AB, Interim report July 1 - September 30, 2023
Summary of the first quarter (2023-07-01 – 2023-09-30) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,1 (-0,8) · Earnings per share* SEK -0.05 (-0.04) · Cash and cash equivalents at the end of the period amounted to MSEK 23,6 (25,2) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. CEO's comment The company's Phase 1 study